The fate of three cancer drugs, and possibly the future financial health of their sponsors, could be on the line Sept. 22 and 23 as the U.S. FDA’s Oncologic Drugs Advisory Committee (ODAC) takes a hard look at the safety-efficacy data for Spectrum Pharmaceuticals Inc.’s Pozenveo, Oncopeptides AB’s Pepaxto and Secura Bio Inc.’s Copiktra. First up in the triple-header is Pozenveo (poziotinib), which is seeking accelerated approval as a second-line treatment for patients with locally advanced or metastatic non-small-cell lung cancer harboring HER2 exon 20 insertion mutations confirmed by an FDA-approved test.
Startup Avelos Therapeutics Inc. raised $8 million in series A funding that will launch the company’s biomarker-driven cancer therapy pipeline using its synthetic lethality platform. Participating in the series A funding were SV Investment, UTC Investment, Quad Investment Management, Timepolio Asset Management, Mirae Asset Venture Investment and Mirae Asset Capital.
Tsd Life Sciences Co. Ltd. has discovered imidazopyridine derivatives acting as protein kinase inhibitors and reported to be useful for the treatment of cancer.
Korea University Research and Business Foundation (KURBF) has identified adamantyl derivatives acting as dipeptidyl peptidase 4 (DPP4; CD26) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, Parkinson's disease, nonalcoholic steatohepatitis (NASH), rheumatoid arthritis, aortic valve stenosis and cerebrovascular and dermatological disorders.
Netris Pharma SAS has entered into a scientific collaboration agreement with Orano SA and the Centre Léon Bérard (CLB) to develop novel antibody-radio conjugates for the treatment of cancer.
Scientists from the University of Lisbon have described how telomeres can establish the maximum damage that a cancer cell can suffer. Above this threshold, the cell would stop dividing and die. The damage comes from the transcription of the telomeres themselves of an RNA molecule called TERRA. When TERRA’s levels increase, the cell can no longer multiply. This mechanism occurs in ALT (alternative lengthening of telomeres) cells, which do not elongate their telomeres through telomerase.
The University of Texas MD Anderson Cancer Center and Radiopharm Theranostics Ltd. have launched Radiopharm Ventures LLC, a joint venture (JV) that will develop radiopharmaceutical therapies for cancer. Radiopharm Theranostics owns 51% of shares in the new entity, while MD Anderson owns 49%.
Jiangxi Jemincare Group Co. Ltd. and Shanghai Jemincare Pharmaceuticals Co. Ltd. have divulged tricyclic hypoxia inducible factor 2-alpha (HIF-2-alpha; EPAS1) inhibitors reported to be useful for the treatment of cancer, von Hippel-Lindau disease, pulmonary hypertension and inflammatory bowel disease.
Insilico Medicine IP Ltd. has described new TRAF2 and NCK-interacting protein kinase (TNIK) and/or mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4; HGK; MEKKK4) inhibitors reported to be useful for the treatment of cancer and fibrosis.
Lamkap Bio Alpha AG's κλ bispecific antibodies include a κ light chain recognizing one target and a λ light chain recognizing a second target. The company has presented data showing the benefit of combining a bispecific antibody targeting CEA (CEACAM5) on tumor cells and CD3 on T cells, NILK-2301, and a bispecific antibody targeting CEA on tumor cells and CD28 on T cells, NILK-3301.
RSS
